Barclays’s Sonoma Pharmaceuticals SNOA Stock Holding History

Barclays’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$565	Buy	+459	New	+$655	﹤0.01%	4990
2019 Q4	–	Hold	0	–	–	–	6773
2019 Q3	–	Hold	0	–	–	–	7092
2019 Q2	–	Sell	-1	Closed	–	–	7248
2019 Q1	$0	Buy	+1	New	+$151	﹤0.01%	7306
2015 Q3	–	Sell	-20	Closed	-$18K	–	7027
2015 Q2	$18K	Buy	+20	New	+$18.7K	﹤0.01%	5745
2014 Q3	–	Sell	-20	Closed	-$54K	–	7812
2014 Q2	$54K	Buy	+20	New	+$59.2K	﹤0.01%	5877

Other funds holding SNOA

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCWS

McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's SNOA Position: Q2 2026 in Review

Barclays opened a new position in Sonoma Pharmaceuticals (SNOA) in Q2 2026: 459 shares worth $565. The stake represents ﹤0.01% of the portfolio and ranks #4990 among its holdings. This is a return to the name: Barclays previously reported a position in SNOA as recently as Q1 2019.

Barclays first reported a position in SNOA in Q2 2014 and has held it in 4 quarters since. The position peaked at $54K in Q2 2014. 14 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

Barclays held 459 shares of Sonoma Pharmaceuticals worth $565 as of Q2 2026.
Sonoma Pharmaceuticals was a new Barclays position in Q2 2026.
Sonoma Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4990 holding.
Barclays first reported a position in Sonoma Pharmaceuticals in Q2 2014 and has held it in 4 quarters since.
Barclays's Sonoma Pharmaceuticals position peaked at $54K in Q2 2014.
14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.